bezafibrate has been researched along with Death, Sudden, Cardiac in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behar, S; Boyko, V; Brunner, D; Doolman, R; Goldbourt, U; Haim, M; Sela, BA; Tanne, D | 1 |
| Battler, A; Behar, S; Benderly, M; Boyko, V; Fisman, EZ; Goldbourt, U; Haim, M; Matas, Z; Tanne, D; Tenenbaum, A; Zimmlichman, R | 1 |
| Agmon, J; Behar, S; Caspi, A; Goldbourt, U; Graff, E; Kaplinsky, E; Kishon, Y; Mandelzweig, L; Reicher-Reiss, H; Weisbort, J | 1 |
3 trial(s) available for bezafibrate and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease.
Topics: Bezafibrate; Case-Control Studies; Coronary Disease; Death, Sudden, Cardiac; Female; Homocysteine; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Factors | 2007 |
C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.
Topics: Bezafibrate; C-Reactive Protein; Coronary Disease; Death, Sudden, Cardiac; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Recurrence; Risk Factors | 2007 |
Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).
Topics: Aged; Algorithms; Bezafibrate; Cholesterol, HDL; Clinical Protocols; Coronary Artery Disease; Death, Sudden, Cardiac; Double-Blind Method; Feasibility Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Triglycerides | 1993 |